Muhsin ÖZDEMİR, Murat ÖZNUR, Evrim ÇİFTÇİ, Beyhan Durak ARAS, Hüseyin ASLAN, Hande SAYGILI, Kevser Setenay ÖNER, Serdar Mustafa ERKASAP, Ayşegül ÖZAKYOL, Özgül PAŞAOĞLU, Oğuz ÇİLİNGİR, Sevilhan ARTAN

Detection of kinase amplifications in gastric adenocarcinomas

To determine the incidences of copy number aberrations of receptor kinases and their relations in Turkish patients with gastric adenocarcinoma. Materials and methods: The prevalence of genomic copy number aberrations of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2)/topoisomerase IIa (TOP2A), centrosome-associated kinase aurora A (AURK A), centrosome-associated kinase aurora B (AURK B), and mesenchymal-epithelial transition factor (MET) genes and polysomies of related chromosomes were analyzed by fluorescent in situ hybridization (FISH) in tumor samples from 35 patients with gastric cancer. Results: There were 28.6%, 65.7%, 20.0%, 17.1%, 60.0%, and 45.7% cases considered FISH-positive for EGFR, MET, HER2, TOP2A, AURK A, and AURK B genes, respectively. Statistically significant associations were determined in detection of amplifications of 1) EGFR gene with chromosome 7 polysomy, 2) MET gene in nonpolysomic chromosome 7 nuclei, 3) HER2/TOP2A genes in nonpolysomic chromosome 17 nuclei, 4) coamplification of HER2/TOP2A in poorly differentiated carcinomas, and 5) AURK A gene in nonpolysomic chromosome 20 nuclei. Most of the aberrations were predominantly seen in poorly differentiated tumors, but a high rate of the amplified MET gene was also detected in moderately differentiated carcinomas. Conclusion: Chromosome 7 polysomy may be responsible for EGFR gene amplifications, and we concluded that MET and AURK A genes amplifications were commonly seen aberrations in gastric adenocarcinomas and may offer information about disease progression and administration of individualized treatment for gastric cancer patients.

Anahtar Kelimeler:

Key words: Receptor protein-tyrosine kinases, aurora kinase, gastric adenocarcinomas

Detection of kinase amplifications in gastric adenocarcinomas

Keywords:

Key words: Receptor protein-tyrosine kinases, aurora kinase, gastric adenocarcinomas,

PDF

___

Nagini S. Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol 2012; 4: 156–169. 2. Yalcin S. Gastric cancer in Turkey — a bridge between west and east. Gastrointest Cancer Res 2009; 3: 29–32. 3. Hudler P. Genetic aspects of gastric cancer instability. Scientific World Journal 2012; 2012:761909.
Karaman A. Role of the p53 tumor suppressor gene in gastric cancer. Turkiye Klinikleri J Med Sci 2003; 23: 67–73.
Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J, Sung JJ. Dysregulation of cellular signaling in gastric cancer. Cancer Lett 2010; 295: 144–153.
Kanta SY, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A. Topoisomerase II alpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum Pathol 2006; 37: 1333–1343.
Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA- 665752. Proc Natl Acad Sci U S A 2006; 103: 2316–2321.
Janjigian YY, Tang LH, Coit DG, Kelsen DP, Francone TD, Weiser MR, Jhanwar SC, Shah MA. MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 1021–1027.
Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, Jiang F, Johnston D, Grossman HB, Ruifrok AC et al. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 2002; 94: 1320– 1329.
Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA, Fiorica JV, Nicosia SV, Cheng JQ. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res, 2003; 9: 1420–1426.
Kulkarni AA, Loddo M, Leo E, Rashid M, Eward KL, Fanshawe TR, Butcher J, Frost A, Ledermann JA, Williams GH et al. DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma. Clin Cancer Res 2007; 13: 6153–6161.
Hegyi K, Egervári K, Sándor Z, Méhes G. Aurora kinase B expression in breast carcinoma: cell kinetic and genetic aspects. Pathobiology 2012; 79: 314–322.
Liang Z, Zeng X, Gao J, Wu S, Wang P, Shi X, Zhang J, Liu T. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer 2008; 8: 363.
Park S, Choi YL, Sung CO, An J, Seo J, Ahn MJ, Ahn JS, Park K, Shin YK, Erkin OC et al. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol 2012; 27: 197–207.
Hechtman JF, Polydorides AD. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma. A review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med 2012; 136: 691–697.
Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797–805.
Kiyose S, Nagura K, Tao H, Igarashi H, Yamada H, Goto M, Maeda M, Kurabe N, Suzuki M, Tsuboi M et al. Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization. Pathol Int 2012; 62: 477–484.
Wang YK, Gao CF, Yun T, Chen Z, Zhang XW, Lv XX, Meng NL, Zhao WZ. Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridization. Mol Cytogenet 2011; 4: 14.
Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol 2011; 8: 492–503.
Takehana T, Kunitomo K, Suzuki S, Kono K, Fujii H, Matsumoto Y, Ooi A. Expression of epidermal growth factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol 2003; 1: 438– 445.
Zhang F, Tang JM, Wang L, Shen JY, Zheng L, Wu PP, Zhang M, Yan ZW. Phosphorylation of epidermal growth factor receptor and chromosome 7 polysomy in gastric adenocarcinoma. J Dig Dis 2012; 13: 350–359.
Okudela K, Woo T, Yazawa T, Ogawa N, Tajiri M, Masuda M, Kitamura H. Significant association between EGFR-mutated lung adenocarcinoma and past illness from gastric cancer or uterine myoma: its implication in carcinogenesis. Lung Cancer 2009; 66: 287–291.
Wang H, Jiang H, Zhou M, Xu Z, Liu S, Shi B, Yao X, Yao M, Gu J, Li Z. Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma. Cancer Lett 2009; 279: 30–38.
Moutinho C, Mateus AR, Milanezi F, Carneiro F, Seruca R, Suriano G. Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer 2008; 8: 10.
Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS et al. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 2011; 25: 1517– 1524.
Shi J, Yao D, Liu W, Wang N, Lv H, He N, Shi B, Hou P, Ji M. Frequent gene amplification predicts poor prognosis in gastric cancer. Int J Mol Sci. 2012; 13: 4714–4726.
Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003; 22: 309–325.
Amemiya H, Kono K, Itakura J, Tang RF, Takahashi A, An FQ, Kamei S, Iizuka H, Fujii H, Matsumoto Y. c-Met expression in gastric cancer with liver metastasis. Oncology 2002; 63: 286– 296.
Huang TJ, Wang JY, Lin SR, Lian ST, Hsieh JS. Overexpression of the c-met protooncogene in human gastric carcinoma– correlation to clinical features. Acta Oncol 2001; 40: 638–643.
Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK, Lee BL, Bang YJ, Kim WH. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 2012; 107: 325–333.
Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol 2011; 18: 53–59.
Grávalos C, Gómez-Martín C, Rivera F, Alés I, Queralt B, Márquez A, Jiménez U, Alonso V, García-Carbonero R, Sastre J et al. Correlation between Her2/neu overexpression/ amplification and clinicopathological parameters in advanced gastric cancer patients: a prospective study. Gastrointestinal Cancers Symposium 2007; 130: Abstract 89.
Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor- associated protease systems. J Clin Oncol 2000; 18: 2201 –2209.
Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16: 273–278.
Kataoka Y, Okabe H, Yoshizawa A, Minamiguchi S, Yoshimura K, Haga H, Sakai Y. HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer 2013; 16: 84–93.
Bilous M, Osamura RY, Rüschoff J, van de Vijver M, Hanna W, Penault-Llorca F, Roche P. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2010; 41: 304–305.
Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol 2010; 32: 57–65.
Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Brümmendorf TH, Bokemeyer C et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009; 40: 769–777.
Moelans CB, van Diest PJ, Milne AN, Offerhaus GJ. Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int 2010; 2011: 674182.
Vader G, Maia AF, Lens SM. The chromosomal passenger complex and the spindle assembly checkpoint: kinetochore- microtubule error correction and beyond. Cell Div 2008; 3: 10–18.
Wang J, Yang S, Zhang H, Song Y, Zhang X, Qian H, Han X, Shi Y. Aurora-A as an independent molecular prognostic marker in gastric cancer. Oncol Rep 2011; 26: 23–32.
Dar AA, Zaika A, Piazuelo MB, Correa P, Koyama T, Belkhiri A, Washington K, Castells A, Pera M, El-Rifai W. Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer 2008; 112: 1688–1698.
Wang W, Zhang N, Wang J, Bu XM, Zhao CH. Inhibition of proliferation, viability, migration and invasion of gastric cancer cells by Aurora-A deletion. Asian Pac J Cancer Prev 2011; 12: 2717 –2720.